773873-50-0 Usage
General Description
2-Hydroxy-3-trifluoromethoxy-benzoic acid, also known as triflusal, is a chemical compound with the molecular formula C8H5F3O4. It is a white crystalline powder that is commonly used as an anti-inflammatory and anti-thrombotic agent. Triflusal is a derivative of salicylic acid and is often prescribed for the treatment and prevention of cardiovascular diseases, such as heart attacks and strokes, by inhibiting platelet aggregation and reducing inflammation. It is also being investigated for its potential anti-cancer properties. Triflusal functions by inhibiting the activity of cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins, thereby reducing pain and inflammation. Additionally, its trifluoromethoxy group enhances its bioavailability and pharmacokinetic properties, making it a promising drug candidate for various therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 773873-50-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,7,3,8,7 and 3 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 773873-50:
(8*7)+(7*7)+(6*3)+(5*8)+(4*7)+(3*3)+(2*5)+(1*0)=210
210 % 10 = 0
So 773873-50-0 is a valid CAS Registry Number.
InChI:InChI=1/C8H5F3O4/c9-8(10,11)15-5-3-1-2-4(6(5)12)7(13)14/h1-3,12H,(H,13,14)
773873-50-0Relevant articles and documents
TRPV1 Antagonists
-
, (2013/06/28)
Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
TRPV1 ANTAGONISTS
-
Page/Page column 69, (2010/04/30)
Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
